Please login to the form below

Innovative pricing and contracting options

With rising treatment prices and healthcare spending, payer organisations are making efforts to contain costs.

With rising treatment prices and healthcare spending, payer organisations are making efforts to contain costs, with the unintended consequence of putting up treatment access barriers. Hence, there is a growing interest in more innovative agreements, such as performance-based (reimbursements tied to conditions around producing outcomes or bridging evidence gaps), finance-based (rebates/discounts for excesses in agreed-upon per-patient or sales thresholds), and value-added (added patient support and educational services).1 These types of agreements, however, are still very broad concepts that do not automatically create competitive advantage. Excellent clinical and financial values are drivers for success in pharma, but without efficient, targeted pricing and contracting schemes, the success of any product is not ensured.2

Innovative pricing and contracting options must arrive at win-win agreements that meet the interests of decision-makers on both sides. Companies need to keep in mind that the innovative pricing and contracting options must address a specific payer concern, create/use a competitive advantage, and fall within legal/regulatory boundaries. Such options, when successfully designed and implemented, can help avoid tendering, or the formalised purchasing based on pre-set criteria that can often lead to price erosion.

Targeting specific payer concerns
Contracting is a tool to enable product use for payers who are sensitive to price. Widening the gross-to-net ratio via innovative net pricing schemes (discounts and rebates) can drive volume among price sensitive payers.3 For new entrants in the biologics space, adopting net pricing options is crucial since some US payers are volume sensitive and may prefer an older competitor drug that is clinically inferior but commands greater demand at present. Volume growth of a new entrant can depend on local coverage, delivery system structures and certain clinical factors, and so it may take time before volume sensitive payers consider it.4

However, pricing and contracting options that win are not necessarily about who gives the most discounts/rebates, but about who uses discounts/rebates to achieve a customer unmet need. Payer interest is not limited to low pricing, value for money, or per-patient cost, but also includes more specific concerns.

Some private insurance firms are focused on growing and retaining their membership through patient support and formulary inclusion of innovative and effective medicines. Pfizer, for example, entered a partnership with Medco Health Solutions Inc. (now part of Express Scripts) in 2011 to identify consumer subgroups and determine which products are most effective in each subgroup, therefore improving personalised care.5 The partnership has initiated precision medicine studies that comply with the Health Insurance Portability and Accountability Act of 1996 (HIPAA).6 It has also led to the creation of Pfizer Link, an online community for clinical trial participants from completed Pfizer-sponsored studies.7

For some products, payers are highly interested in avoiding misuse, which can be costly and a potential legal problem. The use of growth hormones (GH) among adolescents is concerning, particularly if the patient is an athlete or has a bodybuilder relative who could abuse the access to the drug.8 Paediatricians need an active solution to curbing GH abuse.9 A contracting solution in place includes the use of an administration device like Merck’s easypod. Easypod is an electromechanical injection device that delivers the GH deficiency drug Saizen (somatropin) and shows a history of injected doses. Rebates can be provided for any tracked instance of misuse.10

Creating competitive advantage
Identifying and handling specific payer unmet needs through an innovative contracting or pricing agreement requires companies to truly know the customer and be willing to put in the time and commitment that will establish a sustainable competitive advantage with minimal burden for the payer. The contracting option must be based upon either a differential advantage or include technical and practical hurdles that make replication difficult for competitors.

For instance, the online-based project launched in 2013 by AstraZeneca and patient engagement firm Exco InTouch, Me&myCOPD, aims to provide chronic obstructive pulmonary disease (COPD) patients with disease information, personalised coaching, and health management and symptom monitoring tools. The programme provides questionnaires to patients, the results of which are transmitted to clinicians. The current UK trials for the programme aim to produce average savings of £3,500 per hospital admission, which could potentially turn the programme into a standalone service.

Some payer concerns are often neglected, such as their lack of trust in pharma companies.11 Building trust, therefore, can also be turned into a source of competitive advantage. Novo Nordisk, for instance, has partnered with certain cities to curb diabetes. In 2014, the company launched the Cities Changing Diabetes project in cities like Mexico City where diabetes was dubbed as a “ticking time bomb” that would severely and negatively impact the population’s future health.12 The project aims to identify social, cultural, and environmental diabetes drivers as well as key solutions that could be shared with other cities. Without pushing for their products, Novo Nordisk can succeed at promoting their participation in improving global care, which can also build trust with payers and healthcare systems.

If you have enjoyed this article so far, you can read the full article on the Valid Insight website here:

23rd September 2019



Company Details

Valid Insight

+44 (0) 20 3750 9833

Contact Website

152-160 City Road
Kemp House
United Kingdom

Latest content on this profile

RWE Blog 2: Payers use real-world data cautiously
Following our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in our blog Real-world challenges and real-world data, the second instalment of our four-blog series looks at why payers use real-world data cautiously.
Valid Insight
RWE Blog 1: Real-world challenges and real-world data
This is the first of a set of four blogs on real-world data (RWD) and real-world-evidence (RWE), and their role in market access.
Valid Insight
Valid News, Market Access Insights, Issue 3
Wherever you are in the world, it’s important to have a holistic view of what’s happening in the market.
Valid Insight
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published the 21st edition of the EML, recommending the inclusion of 28 new medicines.
Valid Insight
Come meet Valid Insight at booth C2-006 at ISPOR Europe 2019
For the fourth year in succession, we are excited and proud to be exhibiting at this year’s ISPOR 22nd Annual European Congress
Valid Insight
Confidential contracting – the road to flexible pricing
Excellent clinical and financial value are drivers for success in pharma, but without efficient, targeted pricing and adequate confidential contracting schemes, the success of any product is not ensured.
Valid Insight